<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Background <z:chebi fb="0" ids="50924">Sorafenib</z:chebi> is a multi-kinase inhibitor with activity against fms-like tyrosine kinase 3 with internal tandem duplication mutation and Raf kinase among others </plain></SENT>
<SENT sid="1" pm="."><plain>A phase I dose escalation study of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> was conducted in patients with advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and relapsed or refractory <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: Fifty patients received one of two different schedules; Schedule "A": once or twice daily, five days per week, every week for a 21 day cycle, and Schedule "B": once or twice daily, for 14 days every 21 days </plain></SENT>
<SENT sid="3" pm="."><plain>Dose limiting toxicities were grade 3/4 <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, and amylase elevation </plain></SENT>
<SENT sid="4" pm="."><plain>The recommended phase II dose in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> is 400 mg twice daily for both schedules </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Complete remissions or complete remissions with incomplete recovery of platelets were achieved in 5 (10%) patients (<z:hpo ids='HP_0000001'>all</z:hpo> with fms-like tyrosine kinase 3-internal tandem duplication) </plain></SENT>
<SENT sid="6" pm="."><plain>Significant reduction in bone marrow and/or peripheral blood blasts was seen in an additional 17 (34%) patients (<z:hpo ids='HP_0000001'>all</z:hpo> with fms-like tyrosine kinase 3-internal tandem duplication) </plain></SENT>
<SENT sid="7" pm="."><plain>Eleven of these responses (including 3 complete remissions/complete remissions with incomplete recovery) lasted for 2 cycles or beyond </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, <z:chebi fb="0" ids="50924">sorafenib</z:chebi> is active and well tolerated in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> with fms-like tyrosine kinase 3 internal tandem duplication mutation </plain></SENT>
<SENT sid="9" pm="."><plain>Conclusions Additional studies of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> in patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>, particularly those with fms-like tyrosine kinase 3 internal tandem duplication, are warranted, including <z:chebi fb="0" ids="50924">sorafenib</z:chebi>-based combinations </plain></SENT>
<SENT sid="10" pm="."><plain>(ClinicalTrials.gov Identifier: NCT00217646) </plain></SENT>
</text></document>